409 related articles for article (PubMed ID: 22516576)
1. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
Walsh PR; Johnson S
Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
Nester CM; Brophy PD
Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
[TBL] [Abstract][Full Text] [Related]
4. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant recurrence of atypical hemolytic uremic syndrome.
Valoti E; Alberti M; Noris M
J Nephrol; 2012; 25(6):911-7. PubMed ID: 22760880
[TBL] [Abstract][Full Text] [Related]
6. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
7. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
8. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
Verhave JC; Wetzels JF; van de Kar NC
Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180
[TBL] [Abstract][Full Text] [Related]
9. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
[TBL] [Abstract][Full Text] [Related]
10. Haemolytic uraemic syndrome: an overview.
Amirlak I; Amirlak B
Nephrology (Carlton); 2006 Jun; 11(3):213-8. PubMed ID: 16756634
[TBL] [Abstract][Full Text] [Related]
11. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
[TBL] [Abstract][Full Text] [Related]
12. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C
Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
[TBL] [Abstract][Full Text] [Related]
13. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
[TBL] [Abstract][Full Text] [Related]
14. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa M; Grinyó JM; Praga M; Torra R; Vilalta R; Rodríguez de Córdoba S
Nefrologia; 2013 Jan; 33(1):27-45. PubMed ID: 23364625
[TBL] [Abstract][Full Text] [Related]
15. Treatment and management of children with haemolytic uraemic syndrome.
Walsh PR; Johnson S
Arch Dis Child; 2018 Mar; 103(3):285-291. PubMed ID: 28899876
[TBL] [Abstract][Full Text] [Related]
16. Hemolytic uremic syndrome: differential diagnosis with the onset of inflammatory bowel diseases.
Bianchi L; Gaiani F; Vincenzi F; Kayali S; Di Mario F; Leandro G; De' Angelis GL; Ruberto C
Acta Biomed; 2018 Dec; 89(9-S):153-157. PubMed ID: 30561409
[TBL] [Abstract][Full Text] [Related]
17. Atypical haemolytic uraemic syndrome.
Kavanagh D; Goodship TH; Richards A
Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
[TBL] [Abstract][Full Text] [Related]
18. Haemolytic uraemic syndrome.
Kavanagh D; Goodship T
Nephron Clin Pract; 2011; 118(1):c37-42. PubMed ID: 21071971
[TBL] [Abstract][Full Text] [Related]
19. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
de Ville de Goyet M; Detaille T; Godefroid N
J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
[TBL] [Abstract][Full Text] [Related]
20. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M
Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
